医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IDT Offers Preferred Pricing and Early Access to Complete Portfolio of Coronavirus Research Tools

2020年01月29日 AM05:25
このエントリーをはてなブックマークに追加


 

CORALVILLE, Iowa

Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced that it is accepting pre-orders from the global public health and research communities for qPCR primers and probes designed to detect the novel coronavirus, 2019-nCoV, which had an outbreak in Wuhan, Hubei Province, China.

The United States Centers for Disease Control and Prevention (CDC) released a panel of probes and primers on Monday, January 27, 2020, designed for specific detection of the virus. IDT is accepting orders for the panel immediately and will begin shipments next week. The virus detection panels will be manufactured in IDT’s global suite of cleanrooms designed to prevent synthetic template contamination, and the panels will be formulated to meet CDC’s recommended primer-to-probe ratio. To accompany the detection panels, the company has confirmed ‘ready to deliver’ positive and negative controls for 2019-nCoV, which can be used to ensure the accuracy and reliability of test results.

IDT will also provide eBlocks™ and gBlocks™ gene fragments and synthetic genes at preferred pricing, with priority shipping to researchers pursuing rapid vaccine development or exploring therapeutic interventions for 2019-nCoV. To facilitate quick turnaround of orders, the company’s entire gene synthesis support team is standing by to assist with coronavirus projects.

Trey Martin, President of IDT commented, “Fighting emergent pathogens is among the most important efforts that researchers undertake. We’re thankful for all the researchers willing to suit up for these battles, and if we can make their progress faster or easier, we’re going to be there to help them.”

The company has opened a dedicated channel for inquiries relating to 2019-nCoV detection and vaccine development products. Researchers can email coronavirus@idtdna.com to pre-order, and for preferred pricing and priority shipping. IDT’s scientific application support team will address inquiries and guide customers through the process.

Follow IDT on Twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by researchers in diagnostic tests for many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005794/en/

CONTACT

Brian Werger

Manager of Public Relations

800-328-2661 (US & Canada)

+1 319-626-8400 (outside US)

idtpr@idtdna.com

www.idtdna.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高